We came across a bullish thesis on Zai Lab Limited on Value investing subreddit by  mrmrmrj. In this article, we will summarize the bulls’ thesis on ZLAB. Zai Lab Limited's share was trading at $30.00 as of September 4th. Top 5 Best-Selling Cancer Drugs Pixabay/Public Domain Zai Lab (ZLAB), a $3.3B market cap Chinese pharmaceutical company, is growing revenues at 40%+ and positioned to benefit from the country’s rapidly aging demographics. With China expected to undergo a 30-year “old age” shift, demand ...

分组1 - Blueprint Medicines reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of -76.19% [1] - The company posted revenues of $149.41 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.04%, but showing an increase from $96.12 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $171.35 million, and for the current fiscal year, it is -$1.01 on revenues of $728.21 million [7] 分组2 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Blueprint Medicines shares have increased by approximately 2.6% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The estimate revisions trend for Blueprint Medicines is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]